Inventor · disambiguated record
Peter Christian De Visser
Also filed as: DE VISSER PETER CHRISTIAN
5 granted patents·14 pending applications·34 citations·filing 2005–2024
78Inventor score
Files withBIOMARIN TECH BV9PROSENSA TECHNOLOGIES BV3VICO THERAPEUTICS B V3BIOMARIN PHARM INC1PROSENSA HOLDING BV1
Top patents by PatentIndex Score
19 records- 0195US10913946B2RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophyBIOMARIN TECH BV·Filed 2018·Granted Feb 9, 2021·14 cites·3 claims
- 0292US10179912B2RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophyBIOMARIN TECH BV·Filed 2016·Granted Jan 15, 2019·13 cites·9 claims
- 0379US9745576B2RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disordersPROSENSA TECH B V·Filed 2014·Granted Aug 29, 2017·6 cites·6 claims
- 0475US2025011784A1Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disordersVICO THERAPEUTICS B V·Filed 2024·Application pending·0 cites
- 0570US2021108204A1RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular DystrophyBIOMARIN TECH BV·Filed 2020·Application pending·0 cites
- 0668US2023330128A1Oligomers having bicyclic scaffold moietiesBIOMARIN TECH BV·Filed 2023·Application pending·0 cites
- 0765US2022389421A1Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disordersVICO THERAPEUTICS B V·Filed 2022·Application pending·0 cites
- 0864US2023348909A1Dystrophin exon skipping oligonucleotidesBIOMARIN PHARM INC·Filed 2023·Application pending·0 cites
- 0963US11345915B2RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disordersVICO THERAPEUTICS B V·Filed 2019·Granted May 31, 2022·0 cites·25 claims
- 1060US11459358B2Substances for targeting various selected organs or tissuesBIOMARIN TECH BV·Filed 2017·Granted Oct 4, 2022·1 cites·17 claims
- 1159US2022098586A1OligonucleotideBIOMARIN TECH BV·Filed 2021·Application pending·0 cites
- 1259US2015045413A1RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular DystrophyPROSENSA TECHNOLOGIES BV·Filed 2014·Application pending·0 cites
- 1356US2009318403A1Antibiotic compositionPROSENSA TECHNOLOGIES BV·Filed 2007·Application pending·0 cites
- 1454US2018066256A1RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular DisordersBIOMARIN TECH BV·Filed 2017·Application pending·0 cites
- 1548US2011015384A1Sulfurization agent and its usePROSENSA HOLDING BV·Filed 2009·Application pending·0 cites
- 1646US2018028554A1Oligomers Having Bicyclic Scaffold MoeitiesBIOMARIN TECH BV·Filed 2017·Application pending·0 cites
- 1739US2009312521A1Antibiotic drosocin derivativesVAN HOOFT PETRUS ALBERTUS VENA·Filed 2005·Application pending·0 cites
- 1837US2014045763A1Compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type i (dmi)PROSENSA TECHNOLOGIES BV·Filed 2013·Application pending·0 cites
- 1934US2017029820A1Compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type i (dmi)BIOMARIN TECH BV·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Christian De Visser files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →